Zeposia (ozanimod) is not safe to take while pregnant or breastfeeding. Certain factors, including the risks of fetal harm, may determine whether you can take the drug during this time. If you may ...

It assessed the impact of Zeposia on rates of brain volume loss. Patients switching from interferon beta-1a to Zeposia experienced consistent reductions in WBV loss, with similar findings for ...

Final results from the DAYBREAK long-term extension study showed brain volume loss decreased during Phase 3 studies and was sustained with continuous Zeposia treatment for up to 5 years More than ...

In the MS and UC clinical studies, patients who received ZEPOSIA were not to receive concomitant treatment with antineoplastic, non-corticosteroid immunosuppressive, or immune-modulating therapies ...

PRINCETON, N.J.--(BUSINESS WIRE)--Sep 18, 2024-- ...

(2024-03-28 | NYSE:BMY) Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease ...

Zeposia (ozanimod) is a prescription drug that’s used to treat multiple sclerosis and ulcerative colitis. Zeposia can cause side effects that range from mild to serious. Examples include upper ...

Bristol Myers Squibb’s Zeposia is no longer the only S1P receptor modulator on the market for ulcerative colitis, thanks to an FDA approval for what appears to be a more effective drug from Pfizer.